On August 26, 2015, Tech Times spotlighted AFAR’s role in facilitating the planning process for the Taming Aging with Metformin (TAME) trial. The article also included insights from the trial’s lead investigator and AFAR Deputy Scientific Director, Nir Barzilai, MD; Board Member James Kirkland, MD, PhD; and grantee Brian Kennedy, PhD.
This feature discussed both the clinical design and the projected goals of the TAME trial. As Dr. Barzilai stated, “The number one purpose is the idea that we have a drug that we can use in humans that can delay or prevent aging. But the second goal, which is in a way more important if the study works, is to convince the FDA that aging can be a target.”
Researchers believe that by creating an indication for “comorbidities of aging” both personal healthcare costs, related to treatment of end of life diseases and disabilities, and pharmaceutical research costs, related to treating one disease at a time, will decrease.
Read the complete article here and check out other recent pieces on the TAME trial here, here, or here.
Nir Barzilai, MD, is the Director of the Institute for Aging Research at Albert Einstein College of Medicine and a two-time AFAR grant recipient.
Brian Kennedy, PhD, is the President and CEO of the Buck Institute for Research on Aging and the recipient of a 2003 AFAR Research Award and 2008 Julie Martin Mid-Career Award in Aging Research.
James Kirkland, MD, PhD, is the director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic and the 2012 recipient of a Glenn/AFAR Breakthroughs in Gerontology Award.
